Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Hideto Ohhara"'
Publikováno v:
Japanese Journal of Pharmacology. 73:73-82
We compared the antianginal effect of E4080, a novel bradycardic agent with coronary vasodilating properties, with those of a bradycardic agent and some coronary vasodilators in vasopressin-induced anginal model of guinea pigs. An i.v.-administration
Publikováno v:
ChemInform. 23
Publikováno v:
ChemInform. 23
Autor:
Yasuhiro Kabasawa, Takanori Kawamura, Shinji Suda, Kohei Sawada, Hideto Ohhara, Toshiaki Ogawa, Motosuke Yamanaka
Publikováno v:
ChemInform. 24
Publikováno v:
Chemical and Pharmaceutical Bulletin. 40:666-674
The metabolite of loprinone (E-1020) in dogs, 5-(2-aminopyridin-5-yl)-1, 2-dihydro-6-methyl-2-oxo-3-pyridine-carbonitrile (9), was prepared via ozonolysis of imidazo[1, 2-α]pyridinylpyridines and evaluated for positive inotropic activity. Its potenc
Autor:
Yasuhiro Kabasawa, Kouhei Sawada, Toshiaki Ogawa, Shinji Suda, Motosuke Yamanaka, Takanori Kawamura, Hideto Ohhara
Publikováno v:
Chemicalpharmaceutical bulletin. 40(6)
Structural modification of the cardiotonic agent, loprinone (E-1020, 1), suggested by data that it has a less positive chronotropic effect than milrinone (15), led us to find novel bradycardic agents that were structurally different from homoveratryl
Publikováno v:
Chemicalpharmaceutical bulletin. 39(6)
A series of 1,2-dihydro-5-imidazo[1,2-a]pyridinyl-2(1H)-pyridonones was synthesized and evaluated for positive inotropic activity, 1,2-Dihydro-5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2- oxo-3-pyridinecarbonitrile (11a) hydrochloride monohydrate (E-1020
Publikováno v:
Japanese Journal of Pharmacology. 58:398
Publikováno v:
Journal of Molecular and Cellular Cardiology. 13:741-752
Experiments were undertaken to determine if pretreating the animal with coenzyme Q10 (CoQ) protected the cardiac muscle of the isolated heart from the acute toxic injury induced by perfusion with adriamycin. CoQ (15 mg/kg/day) or vehicle alone was in
Publikováno v:
YAKUGAKU ZASSHI. 99:273-279